Separation type: Liquid Chromatography Ion Exclusion
High Performance Liquid Chromatography (HPLC) Method of Imatinib mesylate.
Imatinib mesylate is effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. It is classified as a signal transduction inhibitor. It can be retained on an Obelisc R column, which has both positive and negative ion-pairs embedded in the stationary phase, allowing for the fine tuning and separation of a wide range of compounds with different ionic properties. Imatinib mesylate can be determined isocratically using a simple MS-compatible mobile phase of acetonitrile (ACN) and water with Ammonium Formate (AmFm) buffer and detected by UV at 270nm, ELSD, CAD or LC/MS.
|Obelisc R, 4.6×150 mm, 5 µm, 100A
|Ammonium Formate pH 3.0 – 50 mM
|Class of Compounds
SIELC has developed the Obelisc™ columns, which are mixed-mode and utilize Liquid Separation Cell technology (LiSC™). These cost-effective columns are the first of their kind to be commercially available and can replace multiple HPLC columns, including reversed-phase (RP), AQ-type reversed-phase, polar-embedded group RP columns, normal-phase, cation-exchange, anion-exchange, ion-exclusion, and HILIC (Hydrophilic Interaction Liquid Chromatography) columns. By controlling just three orthogonal method parameters - buffer concentration, buffer pH, and organic modifier concentration - users can adjust the column properties with pinpoint precision to separate complex mixtures.Select options